Loading...
XKRX
019175
Market cap452mUSD
Jul 25, Last price  
24,400.00KRW
1D
-3.37%
1Q
98.70%
Jan 2017
503.21%
Name

Shinpoong Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
5.44
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-27.74%
Rev. gr., 5y
3.11%
Revenues
221.09b
+10.42%
165,922,224,000188,135,653,000217,255,761,000232,060,469,000229,693,072,190221,169,380,010215,962,840,330220,291,937,930195,950,486,360194,147,337,500184,998,400,350187,389,168,040189,721,696,060197,750,767,000189,237,234,930209,287,628,000200,228,582,500221,094,069,680
Net income
-15.39b
L-73.16%
8,843,130,00012,051,001,00021,052,454,00021,734,263,00024,866,240,00014,377,490,0005,437,651,0003,349,617,3601,476,216,010-18,591,699,490904,889,0002,803,780,0005,323,827,0005,002,804,500-11,526,010,680-35,308,829,000-57,325,386,770-15,387,261,000
CFO
-15.15b
L-39.01%
9,765,566,00023,570,779,0009,818,846,00011,357,006,00028,726,635,85030,792,490,39011,453,530,130-48,156,6909,890,504,09018,959,223,22010,148,039,89032,054,460,36019,350,539,80020,062,347,350-71,027,968,120-26,443,578,950-24,847,572,600-15,154,792,750
Dividend
Dec 29, 2020115 KRW/sh
Earnings
Aug 12, 2025

Profile

Shin Poong Pharm.Co.,Ltd. manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products. It also provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; and over the counter products. The company also exports its products to approximately 50 countries. Shin Poong Pharm.Co.,Ltd. was founded in 1962 and is headquartered in Seoul, South Korea.
URL
https://shinpoong.co.kr/
IPO date
Jan 20, 1990
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
221,094,070
10.42%
200,228,582
-4.33%
209,287,628
10.60%
Cost of revenue
191,074,874
212,836,444
302,052,044
Unusual Expense (Income)
NOPBT
30,019,196
(12,607,862)
(92,764,416)
NOPBT Margin
13.58%
Operating Taxes
751,409
3,830,735
527,292
Tax Rate
2.50%
NOPAT
29,267,787
(16,438,597)
(93,291,708)
Net income
(15,387,261)
-73.16%
(57,325,387)
62.35%
(35,308,829)
206.34%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
49,656,063
45,932,476
1,486,762
Long-term debt
6,233,156
1,370,398
2,369,786
Deferred revenue
Other long-term liabilities
3,218,118
2,697,653
3,169,021
Net debt
(12,739,281)
(34,264,824)
(69,634,345)
Cash flow
Cash from operating activities
(15,154,793)
(24,847,573)
(26,443,579)
CAPEX
(5,569,009)
(14,888,220)
(6,228,996)
Cash from investing activities
5,582,713
(16,309,264)
43,196,977
Cash from financing activities
6,196,954
43,238,932
(1,868,611)
FCF
32,361,158
(13,010,092)
(98,164,769)
Balance
Cash
56,460,771
60,461,167
55,916,550
Long term investments
12,167,729
21,106,531
17,574,343
Excess cash
57,573,796
71,556,269
63,026,511
Stockholders' equity
67,805,101
61,192,072
130,632,215
Invested Capital
257,061,743
258,439,163
272,829,072
ROIC
11.36%
ROCE
9.50%
EV
Common stock shares outstanding
9,844
51,262
51,262
Price
10,310.00
-23.74%
13,520.00
-36.08%
21,150.00
-33.80%
Market cap
101,495,362
-85.36%
693,065,742
-36.08%
1,084,196,778
-33.80%
EV
91,125,426
659,997,235
1,016,813,475
EBITDA
41,982,315
(699,472)
(79,960,934)
EV/EBITDA
2.17
Interest
2,631,793
1,718,660
830,991
Interest/NOPBT
8.77%